If you are a resident of Canada who was prescribed and ingested Yasmin between December 10, 2004 and/or YAZ between January 6, 2009, and:
AND you were subsequently diagnosed with one or more of the following conditions:
OR if you are a resident of Canada who, by virtue of a personal relationship with any individual described above, has a derivative claim for damages under Canadian family law legislation.
Your rights may be affected as part of this class action.
A Canada-wide settlement (the “Settlement”) has been reached with Bayer Inc. and other Bayer defendants (collectively, “Bayer”) in class actions in Ontario, Saskatchewan, and Quebec relating to the oral contraceptives Yasmin and YAZ. The class actions raised various allegations relating to blood clots and gallbladder disease and removal. Bayer denies the allegations made in the class actions, makes no admission as to the truth of these allegations, and denies any wrongdoing. The Settlement of the class actions has been approved by the Courts. The allegations made in the class actions have not been proven in court and should not be considered in any way to be medical advice.
A copy of the Settlement Agreement is available here
If you are a Settlement Class Member (as defined below), you may make a Claim for benefits from the Settlement. The deadline to make a Claim is April 9, 2027 (11:59pm Eastern Time).
Click here for more information on how to submit a Claim.
Under the Settlement, Bayer will provide an all-inclusive Settlement Fund of CAD $9,050,000.00. The Settlement Fund will be used, among other things, to pay the costs of notice and administration of the Settlement, the claims of Provincial Health Insurers, Class Counsel legal fees, and benefits for Approved Claimants who are part of the Settlement Class. The final value of benefits for each Approved Claimant will not be determined until all Claims are submitted and considered by the Claims Administrator.
The Courts have approved a Benefits and Distribution Protocol that determines which Settlement Class Members are eligible for benefits and in what amount. The benefits for Approved Claimants will be based on the following points system (see below). Benefits will be paid pro rata based on the number of points assigned to each Approved Claimant, subject to maximum allowable benefits per Claimant.
QUALIFYING CRITERIA | POINTS |
|---|---|
QUALIFYING MEDICAL CONDITIONS RE BLOOD CLOTS | |
Venous Thromboembolism (incl. Pulmonary Embolism and Deep Vein Thrombosis): (1) Proof of Yasmin and/or YAZ ingestion prior to time of injury; (2) Proof of a diagnosis of venous thromboembolism contemporaneous with Yasmin and/or YAZ use, as shown by Evidence. | 100 |
Arterial Thromboembolism (incl. Ischemic Stroke and/or Myocardial Infarction): (1) Proof of Yasmin and/or YAZ ingestion prior to time of injury; (2) Proof of a diagnosis of arterial thromboembolism contemporaneous with Yasmin and/or YAZ use, as shown by Evidence. | 50 |
QUALIFYING MEDICAL CONDITIONS RE GALLBLADDER | |
Gallbladder Disease/Cholecystectomy: (1) Proof of Yasmin and/or YAZ ingestion prior to time of injury; (2) Proof of a diagnosis of gallbladder disease, and/or gallbladder removal (cholecystectomy) within six (6) months of Yasmin and/or YAZ ingestion, as shown by Evidence. | 5 |
QUALIFYING ASSOCIATED FATALITY | |
Fatality (VTE): (1) Proof of Yasmin and/or YAZ ingestion prior to time of fatality; (2) Proof of fatality as a result of a venous thromboembolism; and (3) proof of diagnosis that the fatality was associated with the use of Yasmin and/or YAZ, as shown by Evidence. | 150 |
Fatality (ATE): (1) Proof of Yasmin and/or YAZ ingestion prior to time of fatality; (2) Proof of fatality as a result of an arterial thromboembolism; and (3) proof of diagnosis that the fatality was associated with the use of Yasmin and/or YAZ, as shown by Evidence. | 125 |
FAMILY SETTLEMENT CLASS MEMBER | |
Supporting evidence of a familial relationship to a Settlement Class Member with a Qualifying Medical Condition and/or Associated Fatality, as described above.* *To be made pro rata if more than one (1) family members submit Claims with respect to one (1) Settlement Class Member. | 10% of the points given to the primary Claim. |
A copy of the Benefits and Distribution Protocol is available here.
For the purposes of the Settlement, the Settlement Class is comprised of:
AND who were subsequently diagnosed with arterial thromboembolism, venous thromboembolism, and/or gallbladder disease;
If you previously and validly excluded yourself (opted out) of the class actions, you are NOT eligible to participate in the Settlement.
To make a Claim for benefits from the Settlement, you must complete and submit a Claim Form, along with the necessary supporting Evidence detailed in the Benefits and Distribution Protocol and the Settlement Agreement, to the Claims Administrator before April 9, 2027 (11:59pm Eastern Time). If you do NOT submit your Claim Form and supporting Evidence on time, you will not be eligible for any benefits from the Settlement.
Click here for more information on how to submit a Claim.
Do Nothing | Class members who did not submit an opt-out request are automatically included in the class actions and are bound by the Settlement Agreement. If you do nothing, you will not be eligible to receive benefits from the Settlement, and you will not be able to start a lawsuit, continue a lawsuit, or be part of any other lawsuit against Bayer relating to the legal issues in the class actions. |
|---|---|
Submit a Claim | To be eligible for benefits under this Settlement, you must be a Settlement Class Member and submit a Claim on time. The deadline to submit a Claim is April 9, 2027 (11:59pm Eastern Time). |
We recommend you review the FAQ Page for further details about this Settlement. | |
The deadline to submit a Claim under this Settlement is April 9, 2027 at 11:59 PM EST. Claims may be submitted either by mail, email, or through the applicable online Claim Form available here.
The deadline to object to the Settlement was on October 14, 2025.
The deadline to object to the Settlement in the Court of King's Bench for Saskatchewan was on January 15, 2026.